| Oxford BioMedica (LSE:
OXB) is a biopharmaceutical company specialising
in the development of novel gene-based
therapeutics with a focus on the areas
of oncology and neurotherapy. The pipeline
is focused on the areas of oncology and
neurotherapy. The Company was established
in 1995 as a spin out from Oxford University,
and is listed on the London Stock Exchange.
Oxford
BioMedica's products use
genes as the mediators of a therapeutic
effect and/or immune response. The Company's
gene therapy products deliver therapeutic
molecules in vivo whilst its gene-based
immunotherapy products deliver genes that
recruit the patient's immune system
to mediate a therapeutic effect. The genes
are delivered by the Company's highly
engineered viral systems.
In
addition to its technical expertise in
gene delivery, Oxford BioMedica has
in-house clinical, regulatory and manufacturing
know-how. The development pipeline includes
two novel anti-cancer products in clinical
trials; and two neurotherapy products in
advanced preclinical development for Parkinson's
disease and retinopathy. The Company is
underpinned by an extensive preclinical
and research portfolio and about 70 patent
families, which represents one of the broadest
patent estates in the field.
The
Company has a staff of ~65 split between
its main facilities in Oxford and its wholly
owned subsidiary, BioMedica Inc, in San
Diego, California. Oxford BioMedica has
corporate collaborations with Wyeth, Intervet,
Merck & Co, Amersham, Arius Research
and Kiadis.
|
